Masitinib in combination with riluzole is in clinical development for the treatment of patients with
the amyotrophic lateral sclerosis (ALS), form of motor neurone disease (MND). ALS is a
progressive disease of the nervous system, where nerve cells in the brain and spinal cord that
control voluntary movement gradually deteriorate, causing loss of muscle function and paralysis.
ALS is a debilitating and life-threatening disease.
Masitinib with Riluzole for amyotrophic lateral sclerosis
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Partners-Industry_Motifs_Motifs_Conduction-broadcasting_RGB-scaled_edited_1233.jpg)
Masitinib in combination with riluzole is in clinical development for the treatment of patients with the amyotrophic lateral sclerosis (ALS), form of motor neurone disease (MND).
Indications:
Amyotrophic lateral sclerosis
Therapeutic Areas:
Neurology
Year:
2022